Abstract | OBJECTIVE: METHODS: Patients (n=461) previously receiving ≥1 TNF inhibitor were randomised to subcutaneous injections of placebo, golimumab 50 mg or golimumab 100 mg q4 weeks. Primary endpoint (≥20% improvement in American College of Rheumatology (ACR20) criteria at week 14) findings have been reported for all patients in the trial. Reported herein are further assessments of efficacy/safety among patients receiving golimumab+methotrexate (MTX). RESULTS: Among efficacy-evaluable patients who received MTX at baseline, more receiving golimumab+MTX (n=201) than placebo+MTX (n=103) achieved ACR20 (40.8% vs 14.6%), ACR50 (20.9% vs 3.9%), and ACR70 (11.4% vs 2.9%) responses at week 24. Among the 137 patients who had received only one prior TNF inhibitor ( adalimumab, n=33; etanercept, n=47; and infliximab, n=57), week 24 ACR20 rates were 30.3%, 46.8% and 50.9%, respectively, and thus lowest among those who previously used adalimumab. ACR20 response rates were 44.5% (61/137), 36.2% (17/47) and 23.5% (4/17) among patients who had received one, two or three TNF inhibitors, respectively. Adverse event (AE) rates were comparable across type/number of prior anti-TNF agents, but appeared somewhat higher among patients who discontinued previous TNF inhibitor(s) due to intolerance (37/49, 75.5%) versus lack of efficacy (LOE, 113/191, 59.2%). CONCLUSIONS: Patients with active RA previously treated with ≥1 TNF inhibitor had clinically relevant improvement with golimumab+MTX, which appeared somewhat enhanced among those who received only etanercept or infliximab as their prior TNF inhibitor. Golimumab+MTX safety appeared similar across patients, regardless of TNF inhibitor(s) previously used, with fewer AEs occurring among patients who discontinued prior therapy for LOE.
|
Authors | Josef S Smolen, Jonathan Kay, Eric L Matteson, Robert Landewé, Elizabeth C Hsia, Stephen Xu, Yiying Zhou, Mittie K Doyle |
Journal | Annals of the rheumatic diseases
(Ann Rheum Dis)
Vol. 73
Issue 10
Pg. 1811-8
(Oct 2014)
ISSN: 1468-2060 [Electronic] England |
PMID | 23897769
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. |
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents
- Immunoglobulin G
- Receptors, Tumor Necrosis Factor
- Tumor Necrosis Factor-alpha
- golimumab
- Infliximab
- Adalimumab
- Etanercept
- Methotrexate
|
Topics |
- Adalimumab
- Adult
- Aged
- Antibodies, Monoclonal
(administration & dosage, adverse effects, therapeutic use)
- Antibodies, Monoclonal, Humanized
(adverse effects, therapeutic use)
- Antirheumatic Agents
(administration & dosage, adverse effects, therapeutic use)
- Arthritis, Rheumatoid
(drug therapy)
- Drug Administration Schedule
- Drug Substitution
- Drug Therapy, Combination
- Etanercept
- Female
- Humans
- Immunoglobulin G
(adverse effects, therapeutic use)
- Infliximab
- Injections, Subcutaneous
- Male
- Methotrexate
(administration & dosage, adverse effects, therapeutic use)
- Middle Aged
- Receptors, Tumor Necrosis Factor
(therapeutic use)
- Severity of Illness Index
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|